Free Trial

Arcus Biosciences (NYSE:RCUS) Stock Price Up 10.6% - What's Next?

Arcus Biosciences logo with Medical background

Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) shot up 10.6% during trading on Tuesday . The stock traded as high as $10.22 and last traded at $10.20. 635,508 shares were traded during mid-day trading, a decline of 26% from the average session volume of 861,584 shares. The stock had previously closed at $9.22.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on RCUS. Morgan Stanley lowered their target price on shares of Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating on the stock in a report on Friday, May 9th. Wells Fargo & Company lowered their price target on Arcus Biosciences from $29.00 to $26.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. HC Wainwright upgraded Arcus Biosciences from a "neutral" rating to a "buy" rating and increased their target price for the stock from $18.00 to $24.00 in a research note on Wednesday, February 26th. Barclays lowered their price objective on Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating for the company in a research note on Wednesday, April 23rd. Finally, Wedbush restated an "outperform" rating and set a $33.00 price objective on shares of Arcus Biosciences in a report on Wednesday, May 7th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $24.13.

Check Out Our Latest Research Report on Arcus Biosciences

Arcus Biosciences Trading Down 0.3%

The company has a market cap of $1.01 billion, a price-to-earnings ratio of -3.04 and a beta of 0.88. The business's 50-day simple moving average is $8.33 and its 200-day simple moving average is $11.51. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($1.14) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.12). Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The firm had revenue of $28.00 million during the quarter, compared to analysts' expectations of $38.61 million. During the same period in the previous year, the company earned ($0.05) earnings per share. The business's quarterly revenue was down 80.7% on a year-over-year basis. Research analysts predict that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current fiscal year.

Institutional Trading of Arcus Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. R Squared Ltd bought a new stake in Arcus Biosciences in the fourth quarter valued at approximately $26,000. Strs Ohio bought a new stake in Arcus Biosciences in the 1st quarter valued at $67,000. E Fund Management Co. Ltd. bought a new position in Arcus Biosciences in the first quarter valued at approximately $82,000. Lazard Asset Management LLC raised its holdings in shares of Arcus Biosciences by 3,321.3% during the 4th quarter. Lazard Asset Management LLC now owns 6,261 shares of the company's stock worth $93,000 after buying an additional 6,078 shares in the last quarter. Finally, Knott David M Jr acquired a new position in Arcus Biosciences during the 1st quarter worth approximately $94,000. 92.89% of the stock is currently owned by institutional investors and hedge funds.

About Arcus Biosciences

(Get Free Report)

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.

Recommended Stories

Should You Invest $1,000 in Arcus Biosciences Right Now?

Before you consider Arcus Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.

While Arcus Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Dirt-Cheap Stocks in a Market That’s Getting Expensive
Top 3 Defense Stocks to Profit From $175 Billion Golden Dome
Top 5 Stocks for June: AI Picks That Aren’t NVIDIA

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines